New Hope for People Co-Infected with HIV and Tuberculosis (TB)

Estimados colegas aquí otra información importante sobre la co-ibfección  VIH - TB.

Saludos

Dr. Carlos Erazo

The Cambodia-based study known as CAMELIA demonstrated that the survival of untreated, HIV-infected adults with very weak immune systems and newly diagnosed TB can be prolonged by starting antiretroviral therapy 2 weeks after beginning TB treatment, rather than waiting 8 weeks, as had been standard. This finding is valuable because beginning treatment for HIV in some highly immunocompromised individuals paradoxically can worsen the symptoms of co-infections such as TB, yet waiting too long to start antiretroviral therapy can lead to death. TB accounted for nearly a quarter of the 2 million HIV-related deaths worldwide in 2008. NIAID and the French National Agency for Research on AIDS and Viral Hepatitis co-funded the CAMELIA study.
In late November, CDC published two Morbidity and Mortality Weekly Reports (MMWRs) focused on HIV and TB coinfection—Mortality Among Patients with Tuberculosis and Associations with HIV Status—United States, 1993–2008, and HIV Testing and Treatment Among Tuberculosis Patients—Kenya, 2006–2009.